ALDH7A1 and progressive multifocal leukoencephalopathy: While these characteristics underlie the need to take PDE inhibitors daily, they could in turn provide benefits with respect to the side effects of immunosuppressive therapies, such as natalizumab in patients who are at risk for progressive multifocal leukoencephalopathy (PML) due to impaired immune surveillance [54].